Mirae Asset Global Investments Co. Ltd. Has $4.47 Million Stake in STERIS plc (NYSE:STE)

Mirae Asset Global Investments Co. Ltd. trimmed its holdings in STERIS plc (NYSE:STE) by 2.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,345 shares of the medical equipment provider’s stock after selling 528 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in STERIS were worth $4,473,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Millburn Ridgefield Corp acquired a new position in STERIS in the third quarter valued at about $25,000. Catalyst Capital Advisors LLC acquired a new position in STERIS in the third quarter valued at about $25,000. 1832 Asset Management L.P. acquired a new position in STERIS in the first quarter valued at about $25,000. Global Wealth Management Investment Advisory Inc. acquired a new position in STERIS in the third quarter valued at about $49,000. Finally, NBC Securities Inc. acquired a new position in STERIS in the third quarter valued at about $50,000. 94.69% of the stock is owned by institutional investors and hedge funds.

STERIS Stock Performance

Shares of NYSE STE opened at $201.26 on Tuesday. The stock has a 50 day moving average price of $226.02 and a 200 day moving average price of $218.13. STERIS plc has a 52 week low of $180.54 and a 52 week high of $254.00. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.49 and a current ratio of 2.43. The stock has a market capitalization of $19.89 billion, a PE ratio of 35.24 and a beta of 0.79.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $2.22 EPS for the quarter, beating the consensus estimate of $2.17 by $0.05. STERIS had a return on equity of 13.67% and a net margin of 10.48%. The firm had revenue of $1.40 billion during the quarter, compared to analysts’ expectations of $1.35 billion. During the same period in the prior year, the firm posted $2.02 earnings per share. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. Analysts predict that STERIS plc will post 8.67 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 22nd. Shareholders of record on Friday, February 23rd were paid a $0.52 dividend. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a $2.08 annualized dividend and a yield of 1.03%. STERIS’s dividend payout ratio is 36.43%.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research note on Friday. Stephens reaffirmed an “overweight” rating and set a $250.00 price objective on shares of STERIS in a research report on Friday, February 9th. KeyCorp assumed coverage on STERIS in a research report on Tuesday, February 6th. They set an “overweight” rating and a $253.00 price objective for the company. TheStreet raised STERIS from a “c+” rating to a “b” rating in a research report on Wednesday, February 7th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research report on Thursday, February 8th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $239.60.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.